Stroke and vascular neurology · 2020
CO2 combining power and outcomes in patients with acute ischaemic stroke or transient ischaemic attack.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Anxin, Tian Xue, Gu Hongqiu, Zuo Yingting, Meng Xia, Lv Wei, Li Hao, Wang Yongjun
Аннотация
BACKGROUND AND PURPOSE: The clinical significance of carbon dioxide combining power (CO2CP) in ischaemic cerebrovascular disease is not well established, and the role of CO2CP in the prognosis of acute ischaemic stroke (AIS) or transient ischaemic attack (TIA) has not been reported. The objective of the study was to investigate the associations between CO2CP and clinical outcomes in patients with AIS or TIA.
METHODS: Data were derived from the China National Stroke Registry III. Patients were classified into five groups by quintiles of CO2CP levels and three groups according to the normal range of CO2CP (23-29 mmol/L). Multivariable Cox and logistic regressions were adopted to explore the associations of CO2CP levels with all-cause death and poor functional outcomes (modified Rankin Scale (mRS) 3-6/2-6) at 3 months and 1 year.
RESULTS: Among 9531 patients included in the study, the median (IQR) CO2CP was 24.9 (23.0-27.0) mmol/L. After adjustment for potential confounders, patients in the first CO2CP quintile (21.1-23.3 mmol/L) had higher risk of all-cause death and poor functional outcomes (mRS score of 3-6/2-6) (HR or OR with 95% CI 2.37 (1.32 to 4.25), 1.49 (1.20 to 1.83) and 1.21 (1.03 to 1.42), respectively) compared with those in the fourth quintile. Similar results were found for outcomes at 1 year. Furthermore, all associations were also significant when CO2CP was <23 mmol/L compared with CO2CP of 23-29 mmol/L.
CONCLUSIONS: Decreased CO2CP was associated with high risk of all-cause death and poor functional outcomes in patients with AIS or TIA.
METHODS: Data were derived from the China National Stroke Registry III. Patients were classified into five groups by quintiles of CO2CP levels and three groups according to the normal range of CO2CP (23-29 mmol/L). Multivariable Cox and logistic regressions were adopted to explore the associations of CO2CP levels with all-cause death and poor functional outcomes (modified Rankin Scale (mRS) 3-6/2-6) at 3 months and 1 year.
RESULTS: Among 9531 patients included in the study, the median (IQR) CO2CP was 24.9 (23.0-27.0) mmol/L. After adjustment for potential confounders, patients in the first CO2CP quintile (21.1-23.3 mmol/L) had higher risk of all-cause death and poor functional outcomes (mRS score of 3-6/2-6) (HR or OR with 95% CI 2.37 (1.32 to 4.25), 1.49 (1.20 to 1.83) and 1.21 (1.03 to 1.42), respectively) compared with those in the fourth quintile. Similar results were found for outcomes at 1 year. Furthermore, all associations were also significant when CO2CP was <23 mmol/L compared with CO2CP of 23-29 mmol/L.
CONCLUSIONS: Decreased CO2CP was associated with high risk of all-cause death and poor functional outcomes in patients with AIS or TIA.